| 09th week of 2011 patent applcation highlights part 49 |
| Patent application number | Title | Published |
|---|
| 20110052472 | Process for the Preparation of an Yttrium and Rare Earth Mixed Oxide - The process for the preparation of an yttrium and at least one rare earth mixed oxide comprises the following steps: a. mixing a precursor of the yttrium and at least one rare earth mixed oxide with a flux comprising a barium halide and a boron compound; b. calcining the mixture of step a to obtain said mixed oxide. This mixed oxide may be used as a phosphor in the manufacture of coloured fluorescent lamps, cathode ray tubes and plasma display panels. | 2011-03-03 |
| 20110052473 | METHOD OF MANUFACTURING ACTIVE MATERIAL - Methods of manufacturing an active material capable of improving the discharge capacity of a lithium-ion secondary battery are provided. The first method of manufacturing an active material comprises a hydrothermal synthesis step of heating a mixture containing a lithium source, a phosphate source, a vanadium source, water, and a reducing agent to 100 to 195° C. under pressure; and a heat treatment step of heating the mixture to 500 to 700° C. after the hydrothermal synthesis step. The hydrothermal synthesis step adjusts the ratio [P]/[V] of the number of moles of phosphorus [P] contained in the mixture before heating to the number of moles of vanadium [V] contained in the mixture before heating to 0.9 to 1.2. The second method of manufacturing an active material comprises a hydrothermal synthesis step of heating a mixture containing a lithium source, a phosphate source, a vanadium source, water, and a reducing agent to 200 to 300° C. under pressure and adjusts the ratio [P]/[V] of the number of moles of phosphorus [P] contained in the mixture before heating to the number of moles of vanadium [V] contained in the mixture before heating to 0.9 to 1.5. | 2011-03-03 |
| 20110052474 | INSTALLATION AND METHOD FOR REDUCING THE CONTENT IN ELEMENTS, SUCH AS BORON, OF HALOSILANES - The invention relates to a method for reducing the content in elements of the third main group of the periodic system, especially in boron- and aluminum-containing compounds of technically pure halosilanes for producing high-purity halosilanes, especially high-purity chlorosilanes. The invention further relates to an installation for carrying out said method. | 2011-03-03 |
| 20110052475 | Production of High Purity Silicon from Amorphous Silica - A process to the production of silicon from amorphous silica is disclosed. The amorphous silica is formed from a material rich in silica, especially rice husk ash or silica fume. The process comprises subjecting the amorphous silica to leaching with a lixiviant of aqueous mineral acid, especially hydrochloric acid. Preferably, material rich in silica is roasted at a temperature of not more than 850° C., subjected to leaching and then subjected to a second roasting at a temperature of less than 750° C. The process provides for the production of high purity silicon, especially to the production of solar grade silicon (SoG-Si). | 2011-03-03 |
| 20110052476 | THERMALLY EXFOLIATED GRAPHITE OXIDE - A modified graphite oxide material contains a thermally exfoliated graphite oxide with a surface area of from about 300 m | 2011-03-03 |
| 20110052477 | APPARATUS FOR MANUFACTURING CARBON NANOTUBE HEAT SINK AND METHOD FOR MAKING THE CARBON NANOTUBE HEAT SINK - The present disclosure provides an apparatus for manufacturing a carbon nanotube heat sink. The apparatus includes a board, and a plurality of first and second carbon nanotubes formed on the board. The first carbon nanotubes and the second nanotubes are grown along a substantially same direction from the board. A height difference exists between a common free end of the first carbon nanotubes and a common free end of the second carbon nanotubes. A method for manufacturing multiple carbon nanotube heat sinks is also provided. | 2011-03-03 |
| 20110052478 | METHOD FOR MAKING CARBON NANOTUBE WIRE STRUCTURE - The present disclosure provides a method for making a carbon nanotube wire structure. A plurality of carbon nanotube arrays is provided. One carbon nanotube film is formed by drawing a number of carbon nanotubes from each of the plurality of carbon nanotube arrays, whereby a plurality of carbon nanotube films is formed. The carbon nanotube films converge at one spot. The carbon nanotube wire structure is formed by treating the carbon nanotube films by at least one of a mechanical method and an organic solvent method. | 2011-03-03 |
| 20110052479 | METHOD FOR PREPARING CARBON NANOTUBES, CARBON NANOTUBE FILMS, AND ELECTRONIC DEVICES - A method for preparing carbon nanotubes for synthesizing carbon nanotubes, fabricating carbon nanotube films and electronic devices is provided. The method for preparing carbon nanotubes can repair the defects in side walls of carbon nanotubes under stable condition easily and prepare carbon nanotubes of excellent properties. The method utilizes uric acid solution or ammonia water to treat carbon nanotubes after acidifying the carbon nanotubes by refluxing with nitric acid. The treatment temperature is, for example, 25° C.˜90° C., and treatment time is at least two 2 days. Preferably, the carbon nanotubes are treated with thionyl chloride solution before being treated with uric acid solution or ammonia water. | 2011-03-03 |
| 20110052480 | CHLORINE DIOXIDE GENERATION SYSTEMS AND METHODS - Chlorine dioxide generation systems and methods are disclosed. In some embodiments, an optical analyzer may be positioned along a reactant feed line to measure a reactant concentration. A controller may adjust a flow rate of the reactant in response to information provided by the optical analyzer. | 2011-03-03 |
| 20110052481 | METHOD OF TREATING METALLIFERROUS MATERIALS - There is provided a process of treating a metalliferrous material including at least one metal material fraction. Each one of the at least one metal material fraction includes a respective metal, wherein the respective metal is a transition metal. Each one of the at least one metal material fraction also includes a respective first operative material fraction and a respective second operative material fraction. The respective first operative material fraction consists of an elemental form of the respective metal, and the respective second operative material fraction consists of at least one oxide of the respective metal. The method includes providing reagent material including at least one diatomic halogen and at least one aluminium halide. The reagent material is contacted with the metalliferrous material in a reaction zone so as to effect a reactive process which effects production of an intermediate reaction product including at least one produced metal halide. Each one of the at least one produced metal halide includes a respective metal corresponding to the respective metal of a respective one of the at least one metal material fraction. A separation fraction is separated from the intermediate reaction product. The separation fraction includes at least one recovered metal halide. | 2011-03-03 |
| 20110052482 | METHOD AND APPARATUS TO HELP PROMOTE CONTACT OF GAS WITH VAPORIZED MATERIAL - Vaporizable material is supported within a vessel to promote contact of an introduced gas with the vaporizable material, and produce a product gas including vaporized material. A heating element supplies heat to a wall of the vessel to heat vaporizable material disposed therein. The vessel may comprise an amoule having a removable top. Multiple containers defining multiple material support surfaces may be stacked disposed within a vessel in thermal communication with the vessel. A tube may be disposed within the vessel and coupled to a gas inlet. Filters, flow meters, and level sensors may be further provided. Product gas resulting from contact of introduced gas with vaporized material may be delivered to atomic layer deposition (ALD) or similar process equipment. At least a portion of source material including a solid may be dissolved in a solvent, followed by removal of solvent to yield source material (e.g., a metal complex) disposed within the vaporizer. | 2011-03-03 |
| 20110052483 | APPARATUS FOR PRODUCING HIGH-CONCENTRATION OZONE GAS AND METHOD OF PRODUCING HIGH-CONCENTRATION OZONE GAS - An ozonized gas having a pressure exceeding atmospheric pressure and having a predetermined concentration is supplied to adsorption/desorption columns ( | 2011-03-03 |
| 20110052484 | PROCESS FOR THE PREPARATION OF LITHIUM METAL OXIDES INVOLVING FLUIDIZED BED TECHNIQUES - A method of producing lithium metal oxides can include mixing lithium salt and a metal oxide to form a composition, heating the composition in a first reactor, transferring the composition to a second reactor, and passing the composition through the second reactor to anneal the composition to form lithium metal oxides. The second reactor can be a fluidized bed reactor. The lithium metal oxide can have an average crystal size of between about 5 microns and about 20 microns. | 2011-03-03 |
| 20110052485 | METHOD OF MANUFACTURING FLAKE ALUMINUM OXIDE USING MICROWAVE - The present disclosure suggests a method of manufacturing flake aluminum oxide using a microwave including: performing a pre-treatment on a starting material by grinding the starting material such as alumina hydrate, aluminum salt or the like and classifying particles with an appropriate size; manufacturing transition alumina by performing a heat treatment by means of heating the pre-treated starting material; mixing the transition alumina with molten salt and an additive and then dispersing and grinding the mixed compounds; melting and synthesizing flake aluminum oxide by heating the dispersed and grinded mixture with a microwave as a heating source; separating the molten salt and the additive from the synthesized aluminum oxide; and performing a post-treatment on the flake aluminum oxide by removing a foreign substance such as an additive residue stuck to a surface of a crystal particle of the separated flake aluminum oxide. | 2011-03-03 |
| 20110052486 | MICROPOROUS CARBON MATERIAL, MANUFACTURING METHOD THEREOF, AND HYDROGEN STORAGE METHOD USING MICROPOROUS CARBON MATERIAL - The present invention provides a microporous carbon material capable of expressing functions that supported metal has while maintaining pore functions that the microporous carbon material inherently possesses. The microporous carbon material | 2011-03-03 |
| 20110052487 | Hydrolysis Reactor for Hydrogen Production - In accordance with certain embodiments of the present disclosure, a method for hydrolysis of a chemical hydride is provided. The method includes adding a chemical hydride to a reaction chamber and exposing the chemical hydride in the reaction chamber to a temperature of at least about 100° C. in the presence of water and in the absence of an acid or a heterogeneous catalyst, wherein the chemical hydride undergoes hydrolysis to form hydrogen gas and a byproduct material. | 2011-03-03 |
| 20110052488 | Methods For Treating, Diagnosing, and Monitoring Rheumatoid Arthritis - Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents. | 2011-03-03 |
| 20110052489 | Anti-CD19 Antibodies - The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence. | 2011-03-03 |
| 20110052490 | ENDOSCOPIC MUCOSAL RESECTIONING USING PURIFIED INVERSE THERMOSENSITIVE POLYMERS - One aspect of the invention relates to use of a composition comprising a purified inverse thermosensitive polymer in an endoscopic procedure for gastrointestinal mucosal resectioning in a mammal. Another aspect of the invention relates to a method of gastrointestinal mucosal resectioning, comprising administering submucosally to a region of a gastrointestinal mucosa in a mammal an effective amount of a composition comprising a purified inverse thermosensitive polymer; and surgically resecting said region of gastrointestinal mucosa. Yet another aspect of the invention relates to a kit for use in gastrointestinal endoscopic mucosal resectioning in a mammal, comprising a composition comprising a purified inverse thermosensitive polymer; a syringe; and instructions for use thereof. | 2011-03-03 |
| 20110052491 | GASTRIN RELEASING PEPTIDE COMPOUNDS - New and improved compounds for use in diagnostic imaging or therapy having the formula M—N—O—P—G, wherein M is an optical label or a metal chelator (in the form complexed with a metal radionuclide or not), N—O—P is the linker, and G is the GRP receptor targeting peptide. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided. | 2011-03-03 |
| 20110052492 | Radiohalogenated Benzamide Derivatives And Their Use In Tumor Diagnosis And Tumor Therapy - This invention relates to new radiohalogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy. The radiohalogenated benzamide derivatives according to the invention exhibit novel and especially advantageous properties, in particular with respect to tumor concentration and retardation, liver concentration and blood accumulation. The radiation-therapy doses to be achieved in the tumor, compared to healthy body tissue, are advantageous for the compounds according to the invention. | 2011-03-03 |
| 20110052493 | USE OF POLYPEPTIDES OBTAINED THROUGH SYSTEMATIC MUTATIONS OF SINGLE AMINO ACIDS OF HUMAN AND NON-HUMAN BOX-A OF HMGB1 TO PREVENT AND/OR ANTAGONIZE PATHOLOGIES INDUCED BY HMGB1 - The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE. | 2011-03-03 |
| 20110052494 | H-ANTIGEN BINDING POLYPEPTIDES AND METHODS OF USE - Polypeptides having high specific binding for H-antigen, particularly Lewis y and Lewis b antigens are described. The polypeptides are useful in making conjugates with diagnostic reporter molecules or therapeutic agents such as anticancer agents for binding to epithelial derived tumors or cancer cells which overexpress such antigens. | 2011-03-03 |
| 20110052495 | USE OF FULLERENES IN PHOTOACOUSTIC IMAGING - Fullerenes, when irradiated with electromagnetic radiation, generate acoustic waves. A photoacoustic tomography method using a material comprising fullerenes is disclosed that includes irradiating the material with a radiation beam such as a laser. The resultant photoacoustic effect produced by the material is detected by at least one detector. A photoacoustic tomography system using a material comprising fullerenes is also described. | 2011-03-03 |
| 20110052496 | HOLLOW NANOPARTICLES AND USES THEREOF - Aspects of the invention provide hollow nanoparticles and uses thereof. In particular, the invention provides membrane-enclosed vesicles comprising a truncated form of an HBsAg S protein lacking one or two of its amino-terminal transmembrane domains. | 2011-03-03 |
| 20110052497 | Minimally Invasive Systems and Methods for In Vivo Testing of Materials - Implantable material testing devices and method of testing materials in an animals are provided. In one embodiment, a method of testing a material in an animal includes associating the material with a retention frame to form a testing device. The retention frame movable between a first shape suited for insertion through a deployment instrument and a second shape suited for retention in the animal. The testing device is inserted in the first shape into the deployment instrument and is driven through the deployment instrument into the animal. Once in the animal, the testing device is permitted to assume the second shape so that the testing device is retained in the animal for a testing period. The testing device is removed from the animal after the testing period is complete, and the material is analyzed. The material may be analyzed for biofilm formation, encrustation, or degradation. The animal also may be analyzed for infection or other reactions to the material. Tissue may be collected from the animal, and the tissue may be analyzed. The testing period may be between about 1 day and about 90 days. | 2011-03-03 |
| 20110052498 | Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders - A vaccine for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual comprises a therapeutically effective amount of isolated stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized oligomer of the α-synuclein. An antibody for delaying an onset of or for treatment of an α-synuclein-related disorder in an individual binds soluble α-synuclein. Methods for delaying an onset of for treatment or for prevention of an α-synuclein-related disorder employ the vaccine or antibody. Methods of detecting α-synuclein oligomers employ the antibody. | 2011-03-03 |
| 20110052499 | BABOON HOMOLOG OF HUMAN CD147 - Polynucleotide sequences encoding a baboon homolog of human CD147 and polypeptides obtainable form the polynucleotides and uses are disclosed. | 2011-03-03 |
| 20110052500 | TAJ in Neuronal Function - The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist. | 2011-03-03 |
| 20110052501 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development. | 2011-03-03 |
| 20110052502 | MicroRNA Signatures Associated with Human Chronic Lymphocytic Leukemia (CCL) and Uses Thereof - Methods and compositions for the diagnosis, prognosis and/or treatment of leukemia associated diseases are disclosed. | 2011-03-03 |
| 20110052503 | BIODEGRADABLE CONTRAST AGENTS - The present invention provides a radio-opaque composition comprising a cleavable, preferably enzymatically-cleavable, derivative of a physiologically tolerable organoiodine compound and a non-acrylic polymer wherein said derivative is incorporated in said non-acrylic polymer. | 2011-03-03 |
| 20110052504 | CONTRAST AGENTS - The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing two linked iodinated phenyl groups of the general formula R—N(CO—CH | 2011-03-03 |
| 20110052505 | Post-biopsy cavity treatment implants and methods - A post-biopsy cavity treatment implant includes a radiopaque element, a core portion and a shell portion. The core portion is coupled to the radiopaque element, and includes a first porous matrix defining a first controlled pore architecture. The shell portion is coupled to the core portion and includes a second porous matrix defining a second controlled pore architecture that is different from the first controlled pore architecture. | 2011-03-03 |
| 20110052506 | Stable Aerosol Topical Foams Comprising a Hypochlorite Salt - Described herein are compositions useful in the treatment of atopic dermatitis and other skin conditions, which compositions exhibit enhanced stability. The compositions contain a hypochlorite salt, useful for its antimicrobial properties, and are non-irritating when applied to the skin. The compositions also provide enhanced moisturizing properties. The compositions can be formulated into a topical aerosol foam with inert, non-flammable propellants, such as hydrofluoroalkanes, and may be used in cosmetics or pharmaceuticals. | 2011-03-03 |
| 20110052507 | ORAL CARE COMPOSITIONS COMPRISING CASEIN, OVALBUMIN, WHEY OR SOY PROTEIN - The present invention relates to the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for combating (i.e. helping to prevent, inhibit and/or treat) dental erosion and/or tooth wear caused by subsequent exposure to acid. | 2011-03-03 |
| 20110052508 | PEPTIDE-BASED ORAL CARE SURFACE REAGENTS FOR PERSONAL CARE - Peptides have been identified that bind to oral surfaces such as teeth and gums. Peptide based oral care reagents have been created by couple such peptides to oral care benefit agents such as whiteners. | 2011-03-03 |
| 20110052509 | COMPOSITIONS COMPRISING BASIC AMINO ACID AND SOLUBLE CARBONATE SALT - This invention relates to compositions comprising a basic amino acid free or salt form and a soluble carbonate or bicarbonate salt. | 2011-03-03 |
| 20110052510 | Tooth Movement Activating Compound - The invention relates to the development of a food or edible product of oleic origin, which acts as a dental lubricant and is intended to reduce friction between orthodontic wires and brackets, thereby providing low, more continuous physiological forces and, consequently, a significant reduction in orthodontic treatment times. The invention is characterised in that it comprises a base element of oleic origin and a stabilising or mixing element and in that it is prepared so that it can also include different additives having sanitary-hygienic properties. The invention is also characterised in that it can be applied easily and immediately and in that it is formulated with different viscosities in order to cover all orthodontic treatment phases. | 2011-03-03 |
| 20110052511 | NOVEL USE OF ORGANIC COMPOUNDS - The present invention is directed to the use of a compound selected from the group consisting of β-carotene, lutein, lycopene and β-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 for maintaining the energy metabolism, the energy flow and/or the energy production in skin or of skin of animals including humans, for maintaining the respiratory function of the skin of animals including humans, for energizing the skin, maintaining and supporting the radiance and natural glow of the skin of animals including humans and for promoting a healthy appearance of the skin of animals including humans for preventing UV-A radiation-induced mtDNA mutagenesis in skin of animals including humans, as well as for the manufacture of a composition, preferably an orally applicable composition, for these uses and the corresponding methods. The present invention is further directed to the use of a compound selected from the group consisting of β-carotene, lutein, lycopene and β-cryptoxanthin, and mixtures thereof and combinations thereof with CoQ-10 in sunscreens as well as daily care products to improve their photoprotective potential, as well as to their use as effective micronutrients for skin maintenance. Furthermore the present invention is directed to compositions, preferably orally applicable compositions, comprising a certain amount of at least one compound selected from the group consisting of β-carotene, lutein, lycopene and β-cryptoxanthin and mixtures thereof and combinations thereof with CoQ-10 as active ingredient, characterized in that the amount is effective for such uses as mentioned above. | 2011-03-03 |
| 20110052512 | COMPOSITION CONTAINING A HYDROXYLATED DIPHENYLMETHANE DERIVATIVE - The invention relates to a composition in the form of an oil-in-water emulsion containing an ester of fatty acid and of polyethylene glycol, an additional surfactant chosen from esters of C | 2011-03-03 |
| 20110052513 | CATIONIC SURFACTANT COMPOUNDS, USE THEREOF AS CONDITIONER, COSMETIC TREATMENT METHOD, AND COSMETIC OR PHARMACEUTICAL COMPOSITIONS COMPRISING SAME - The present patent application relates to novel surface-active cationic compounds, to their use, in particular as hair conditioning agent, to a cosmetic treatment method, in particular for the hair, employing the said compounds, and to the cosmetic or pharmaceutical compositions, in particular hair compositions, comprising the said surfactants. | 2011-03-03 |
| 20110052514 | USE OF NATURAL ACTIVE SUBSTANCES IN COSMETIC OR THERAPEUTIC COMPOSITIONS - The invention relates to cosmetic or therapeutic compositions that contain hydrolysed yeast proteins as an active ingredient, to the use of said cosmetic or therapeutic compositions, and to a method for cosmetic treatment. | 2011-03-03 |
| 20110052515 | AVERMECTIN/BENZOYL PEROXIDE COMPOSITIONS FOR TREATING AFFLICTION OF THE SKIN, E.G., ROSACEA - Pharmaceutical/dermatological compositions containing at least one avermectin compound, e.g., ivermectin and benzoyl peroxide, are useful for treating afflictions of the skin, especially rosacea. | 2011-03-03 |
| 20110052516 | SUNSCREENS - The present invention relates to the use of phosphate ester surfactants for increasing the sun protection factors (SPF's) of topical compositions which comprise at least on UV-filter substance. Furthermore, the invention relates to topical compositions comprising a phosphate ester surfactant and at least 4 wt-% of butyl methoxydibenzoylmethane in combination with further UV-filter substances. | 2011-03-03 |
| 20110052517 | Cosmetic Uses of Modified Stressed Yeast Extracts and Related Compositions - Cosmetic compositions comprising a metal-complexed peptide fraction of stressed yeast extracts and/or a calcium influx inhibitor are disclosed, as well as methods of using such compositions to impart exfoliating, anti-aging, anti-lipid, anti-inflammatory, and/or lightening benefits to the skin; and/or lightening benefits to the hair. These compositions are believed to have modulatory activity against at least one biochemical pathway implicated in skin aging, inflammation, lipid synthesis, and melanin production. | 2011-03-03 |
| 20110052518 | BLEACHING/HIGHLIGHTING COMPOSITION CONTAINING CALCIUM SALTS - The present invention relates to bleaching composition for keratin fibres, especially human hair, comprising at least one compound with bleaching and/or highlighting effect and a calcium salt. Further object of the present invention is the use of at least one calcium salt in a bleaching and/or highlighting composition for keratin fibres, especially for human hair, comprising at least one compound with bleaching and/or highlighting effect for preventing temperature increase going above 40° C., preferably above 45° C. and more preferably above 50° C. in a period of at least 60 min after mixing water free bleaching and/or highlighting composition and oxidizing lotion. | 2011-03-03 |
| 20110052519 | PEPTIDE DERIVATIVES USEFUL IN THE TREATMENT, CARE OR CLEANSING OF THE SKIN, MUCOSAE, SCALP OR NAILS - The invention relates to peptide derivatives of general formula (I): | 2011-03-03 |
| 20110052520 | USE OF A COMPOSITION AND PROCESS INVOLVING THE USE OF A NON-HYDROXIDE BASE AND A PROTEIN DENATURANT WITH HEAT FOR RELAXING OR STRAIGHTENING HAIR - A process for straightening or relaxing hair involving the steps of: (a) providing a hair straightening/relaxing composition containing: (i) from about 0.1 to about 50% by weight of at least one non-hydroxide base; (ii) from about greater than 0% to about 50% of at least one protein denaturant; and (iii) remainder, to 100%, a cosmetically acceptable medium, all weights based on the weight of the hair straightening/relaxing composition; (b) contacting the hair with the hair straightening/relaxing composition to form treated hair; (c) optionally, rinsing the hair straightening/relaxing composition from the treated hair; (d) optionally, contacting the treated hair with a non-volatile oil; and(e) smoothing the treated hair using a combination of heat and means for physically smoothing hair. | 2011-03-03 |
| 20110052521 | Oil-In-Water Organopolysiloxane Emulsion Composition, Cosmetic Ingredient Comprising This Composition, And Method Of Producing A Hair Cosmetic Using This Composition - To provide a highly storage-stable nonionic oil-in-water organosiloxane emulsion composition that substantially does not contain ionic surfactant and that on a long-term basis does not undergo separation of the emulsion composition. An oil-in-water organosiloxane emulsion composition that characteristically comprises (A) 100 weight parts of organosiloxane, (B) 0.5 to 35 weight parts of organic-modified organosiloxane, (C) 0.5 to 35 weight parts of nonionic surfactant, (D) 0.5 to 15 weight parts of water-soluble solvent, and (E) water, wherein the content of (F) ionic surfactant in the composition is less than 0.1 weight part per 100 weight parts component (A). | 2011-03-03 |
| 20110052522 | COSMETICS COMPRISING CISTUS PLANT EXTRACTS - The present invention relates to the use of an extract from | 2011-03-03 |
| 20110052523 | ORGANOPOLYSILOXANE COMPOUND AND AMIDOAMINE COMPOUND, AND COSMETIC PREPARATION - An organopolysiloxane compound having a weight average molecular weight of 300 to 200,000 and having in one molecule at least one organic group represented by the following formula (1) and at least one selected from (SiO | 2011-03-03 |
| 20110052524 | VERTEBROPLASTY METHOD USING AN ADDITION CURABLE POLYSILOXANE SYSTEM - The invention relates generally to treatments of disordered bony structures, in particular to vertebroplasty compositions and methods and, more specifically, to treating vertebral bodies in living creatures, in particular, human beings and also compositions suitable for use in such methods and preparation and use of such compositions. According to the invention the composition to be used is an addition curable polysiloxane system. | 2011-03-03 |
| 20110052525 | Breaking Immunological Tolerance with a Genetically Encoded Unnatural Amino Acid - The present invention comprises methods and compositions for producing and/or enhancing an immunological response in a subject against a target moiety such as a disease-related moiety by administration of an antigenic version of the target moiety having one or more unnatural amino acid and/or by administration of an antibody against a version of a target moiety having one or more unnatural amino acid which antibody is cross reactive with the natural target moiety. | 2011-03-03 |
| 20110052526 | METHOD AND COMPOSITION FOR NEOCHONDROGENESIS - A method of neochondrogenesis, where following microfracture surgery or subchondral drilling, includes administering injections of an effective amount of a composition to the damaged, affected connective tissue, for example knee joint cartilage. The composition includes a mixture of hyaluronic acid combined with harvested stem cells, for example autologous peripheral blood-derived stem cells. | 2011-03-03 |
| 20110052527 | IMIDAZOPYRIDINYL THIAZOLYL HISTONE DEACETYLASE INHIBITORS - A compound of general Formula (I) having histone deacetylase (HDAC) and/or CDK inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound. | 2011-03-03 |
| 20110052528 | Neuroprotective macrocyclic compounds and methods for their use - Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions. | 2011-03-03 |
| 20110052529 | METHODS AND COMPOSITIONS FOR EXPANDING T REGULATORY CELLS - The present invention provides methods and compositions for expanding Treg cells ex vivo or in vivo using one or more conjugates comprising a costimulatory moiety that stimulates at least one of three signals involved in Treg cell development and/or using dendritic cells pulsed with antigens and modified to display TGF-β, or hematopoetic stem cells or bone marrow cells modified to display TGF-β. The methods and compositions are useful, for example, in the treatment and prevention of autoimmune disease, including Type 1 diabetes and in preventing foreign graft rejection, as well as to establish mixed chimerism, induce tolerance to autoantigens, alloantigens or xenoantigens, beta cell regeneration, prevention of foreign graft rejection, and treatment of a genetically inherited hematopoietic disorder. | 2011-03-03 |
| 20110052530 | ADOPTIVE CELL THERAPY WITH YOUNG T CELLS - The invention provides a method of promoting regression of a cancer in a mammal comprising (i) culturing autologous T cells; (ii) expanding the cultured T cells; (iii) administering to the mammal nonmyeloablative lymphodepleting chemotherapy; and (iv) after administering nonmyeloablative lymphodepleting chemotherapy, administering to the mammal the expanded T cells, wherein the T cells administered to the mammal are about 19 to about 35 days old and have not been screened for specific tumor reactivity, whereupon the regression of the cancer in the mammal is promoted. | 2011-03-03 |
| 20110052531 | CYCLIC GLYCYL-2-ALLYL PROLINE AND ITS USE IN TREATMENT OF PERIPHERAL NEUROPATHY - Embodiments of this invention provide methods for therapeutic use of cyclic G-2-allylProline (cG-2-allylP) to treat peripheral neuropathies, including toxin-induced peripheral neuropathy and diabetic as well as manufacture of medicaments including tablets, capsules, and other orally active compositions containing cG-2-allylP, as well as injectable solutions that are useful for treatment of such conditions. | 2011-03-03 |
| 20110052532 | Pharmaceutical composition comprising a cytokine - The present invention relates to a pharmaceutical composition comprising, (i) a cytokine and, (ii) a compound of the general formula (Ih) or pharmaceutically acceptable salts thereof with an acid or a base, or pharmaceutically acceptable prodrugs or a stereoisomer thereof. Exemplary cytokines are selected from the following group of cytokine families, (i) the four α-helix bundle family, which consists of, (a) the IL-2 subfamily, (b) the interferon (IFN) subfamily and, (c) the IL-10 subfamily, (ii) the IL-1 family, (iii) the IL-17 family and, (iv) chemokines. | 2011-03-03 |
| 20110052533 | Compositions and Methods for Cartilage Repair - Autologous compositions and methods are provided for cartilage repair in patients in need thereof. Some aspects include combinations of platelet-based materials with chondrogenesis inducing agents in the presence or absence of cell-based therapies. | 2011-03-03 |
| 20110052534 | Imidazopyridazine Compounds for Treating Viral Infections - Disclosed are compounds and compositions of Formula (I), pharmaceutically acceptable salts and solvates thereof, and their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses: | 2011-03-03 |
| 20110052535 | COMPOSITIONS FOR TREATING AN INFLAMMATORY AUTOIMMUNE CONDITION - The present invention relates to a medicament comprising human Tr1 cells directed to a human HSP and methods for treating an inflammatory autoimmune condition. | 2011-03-03 |
| 20110052536 | METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION - Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of treating HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like. | 2011-03-03 |
| 20110052537 | NITRO-BASED EXPLOSIVE REMEDIATION - Embodiments of techniques for remediating soil contaminated with compounds, particularly nitro-based explosives, are disclosed. Plants capable of taking up the compounds are grown within contaminated soil for a period of time. The plants are exposed to anaerobic microbes in the rumen of a ruminant animal. The ruminal anaerobic microbes degrade the remediable compounds and render them substantially nontoxic to the animal. In some embodiments, the remediable compounds are nitroaromatic compounds, and are degraded by nitroreductases. In other embodiments, microbes are transferred from a consortium enriched in microbes capable of degrading the remediable compounds to a ruminant animal that lacks microbes capable of degrading the remediable compounds. In other embodiments, methods for isolating and identifying ruminal anaerobic microbes capable of degrading remediable compounds are disclosed. | 2011-03-03 |
| 20110052538 | PROBIOTIC/NON-PROBIOTIC COMBINATIONS - This invention pertains to a method of promoting gastrointestinal health by ingesting a composition comprising one or more probiotic microorganisms, one or more carbohydrate sources, and one or more resistant protein products. Large intestinal health is benefited by one or more of the following: increased fecal weight, lower fecal pH, increased carbohydrate fermentation, and amelioration of protein fermentation. | 2011-03-03 |
| 20110052539 | ONCOLYTIC RHABDOVIRUS - Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo. | 2011-03-03 |
| 20110052540 | Non-Aggregating Virus Formulation - The present invention is a composition comprising a virus, a polyol and a zwitteronic compound. The present invention is also an assay for viral aggregation, which comprises analysing the size of the viral particles in a sample, wherein the particles are in admixture with a polyol, and determining from the size whether the sample contains substantially only acceptable, non-aggregated particles. | 2011-03-03 |
| 20110052541 | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more | 2011-03-03 |
| 20110052542 | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - Disclosed herein is a novel bacteriophage which has specific bactericidal activity against one or more | 2011-03-03 |
| 20110052543 | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more | 2011-03-03 |
| 20110052544 | NOVEL BACTERIOPHAGE AND ANTIBACTERIAL COMPOSITION COMPRISING THE SAME - Disclosed herein are is a novel bacteriophage which has specific bactericidal activity against one or more | 2011-03-03 |
| 20110052545 | Regeneration system, its production and use - The present invention relates to a tissue-maintaining colony-forming unit (TM-CFU), a method of preparing the same, a pharmaceutical composition comprising the TM-CFU, the use of the TM-CFU for the manufacture of a pharmaceutical composition, and a method of determining the effect of at least one stimulus on the TM-CFU or a cellular subpopulation thereof. | 2011-03-03 |
| 20110052546 | Inhibition of SHIP to Enhance Stem Cell Harvest and Transplantation - The instant invention teaches the inhibition of SHIP expression, or function for the increased efficacy of autologous stem cell transplants. In another embodiment, interference with SHIP function can be used to temporarily expand and mobilize the hematopoietic stem cell compartment to assist with leukapheresis, to promote hematopoietic recovery after myeloablation treatments, to deplete target stem cell clones (such as leukemic clones and other tumor stem cell types), and to deplete, or damage, the repopulating ability of the endogenous hematopoietic stem cell pool in order to allow transplanted hematopoietic stem cells to better home and engraft and to promote in vivo expansion and mobilization of other organ-specific stem cell populations (e.g., mesenchymal, mammary). | 2011-03-03 |
| 20110052547 | RAPAMYCIN-RESISTANT T CELLS AND THERAPEUTIC USES THEREOF - Methods for generating highly enriched Th1/Tc1 and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer. | 2011-03-03 |
| 20110052548 | CELL CULTURE MEDIA TO DIFFERENTIATE EMBRYONIC STEM CELLS INTO NEURONAL LINEAGES - This invention provides compositions for differentiating an isolated embryonic stem cell or an isolated embryoid body into neuronal progenitor cells and methods for using same. | 2011-03-03 |
| 20110052549 | CELL CULTURE DEVICE TO DIFFERENTIATE STEM CELLS IN A SPECIFIC ORIENTATION - Methods and compositions for aligning cell growth is provided by this invention by contacting at least one isolated cell with a device, wherein the device comprises a plurality of continuously orientating substantially parallel structures on the surface of the device, and culturing the cell under conditions that favor division of the at least one cell into a population of cells, thereby growing the population of cells in a substantially parallel orientation. | 2011-03-03 |
| 20110052550 | Therapeutic Uses of Allogeneic Myeloid Progenitor Cells - Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients. | 2011-03-03 |
| 20110052551 | CARDIAC MYOCYTE MORPHOGENIC COMPOSITIONS AND METHODS OF USE THEREFOR - Disclosed are methods for inducing cardiomyogenic differentiation in cells that are competent for differentiation along the cardiomyogenic lineage such as certain unfractionated bone marrow mononuclear cells (BMMNCs). In some embodiments, the methods include contacting a plurality of unfractionated, density gradient-separated BMMNCs with a cardiomyocyte differentiation-inducing amount of a Wnt11 gene product for a time and under conditions sufficient to induce cardiomyocyte differentiation in at least a subset of the BMMNCs. Also provided are methods for treating an injury to cardiac tissue in a subject using cells that have been induced to differentiate along the cardiomyogenic lineage, recombinant host cells comprising an expression vector that encodes a Wnt11 polypeptide or a functional fragment thereof, and systems for inducing cardiomyogenic differentiation in a cultured cell. | 2011-03-03 |
| 20110052552 | COMPOSITIONS TO EFFECT NEURONAL GROWTH - Compositions containing neurogenic agents for inhibition of neuron death and inducing proliferation of neural cells are disclosed | 2011-03-03 |
| 20110052553 | STRAIN OF LACTOBACILLUS PLANTARUM LP28 AND ITS USE IN TREATING HYPERSENSITIVITY REACTIONS - A new strain of | 2011-03-03 |
| 20110052554 | METHODS FOR OFF-THE- SHELF TUMOR IMMUNOTHERAPY USING ALLOGENEIC T-CELL PRECURSORS - The inventive subject matter relates to methods for treating a T-cell deficiency in a subject in need thereof, comprising administering to said subject a T-cell precursor isolated from an allogeneic donor, provided that said allogeneic donor is not MHC-matched to said subject. The inventive methods can be further enhanced by genetic engineering for targeted immunotherapy. | 2011-03-03 |
| 20110052555 | PESTICIDE COMPOSITION COMPRISING A TETRAZOLYLOXIME DERIVATIVE AND A FUNGICIDE OR AN INSECTICIDE ACTIVE SUBSTANCE - The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against fungal diseases or insect damages, and the corresponding methods of protection by application of the said composition. More precisely, the subject of the present invention is a pesticide composition based on a tetrazolyloxime derivative and a fungicide or an insecticide active substance or compound. | 2011-03-03 |
| 20110052556 | PHARMACEUTICAL COMPOSITION COMPRISING RACETAM AND CARNITINE AND PROCESS FOR ITS PREPARATION - The present invention refers to a pharmaceutical composition comprising racetam and carnitine. Said pharmaceutical composition may further comprise coenzyme Q10 and/or agent associated with mitochondrial and/or metabolic disturbance, such as hypocholesterolemic agent of the statins group, a hypoglycemic agent, or an antiepileptic agent. The invention also includes a method of treatment for mitochondrial disturbances comprising administration of the pharmaceutical composition of the invention. | 2011-03-03 |
| 20110052557 | PHYTOCOMPOSITION HAVING ANTIMICROBIAL ACTIVITY - The present invention is directed to a method and a composition for producing and using a plant-based biocidal solution. The plant-based biocidal solution contains a bioactive material and a plant-based substance formed from the cellular material of a plant. The plant-based substance is capable of binding to the bioactive material. In some embodiments, the bioactive material is hydrogen peroxide. The hydrogen peroxide can be added exogenously or generated endogenously. In accordance with further embodiments, the plant-based biocidal solution can be applied to a target, thereby impairing the target. In some embodiments, the target can be a pathogen. In accordance with another embodiment, the plant-based substance of the plant-based biocidal solution can form a microscopic cluster, a complex, or an aggregate for providing sufficient bioactive material to overcome the defense mechanism of the target. | 2011-03-03 |
| 20110052558 | MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES - The subject invention concerns a method of inhibiting an RNA virus infection within a patient by increasing the amount of 2-5 oligoadenylate synthetase (2-5 AS) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administering a nucleotide encoding 2-5 AS, or at least one catalytically active fragment thereof, such as the p40, p69, p100 subunits, to a patient in need thereof. The present inventors have determined that overexpression of 2-5AS causes a reduction in epithelial cell damage, reduction in infiltration of mononuclear cells in the peribronchiolar and perivascular regions, and reduction in thickening of the septa in the lungs. Levels of chemokines, such as MIP1-α, are also reduced upon overexpression of 2-5AS. The subject invention also pertains to pharmaceutical compositions containing a nucleotide sequence encoding 2-5 AS and a pharmaceutically acceptable carrier, as well as vectors for delivery of the 2-5 AS nucleotide sequence. | 2011-03-03 |
| 20110052559 | DOSE ESCALATION ENZYME REPLACEMENT THERAPY FOR TREATING ACID SPHINGOMYELINASE DEFICIENCY - The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B. | 2011-03-03 |
| 20110052560 | Method for Increasing the Activity of the Immune System of a Mammal at Risk of Inflammatory Diseases - The present invention relates to methods for increasing the activity of the immune system and, especially, to methods for increasing the activity of the immune system by modulation of endogenous ectophosphatase levels. According to a particularly preferred embodiment the present invention relates to methods for the prophylaxis of mammals, and especially human mammals, at risk of inflammatory diseases such as mammals suffering from conditions such as surgery, digestive tract diseases, respiratory diseases, skin diseases, burn wounds, smoke inhalation, intoxication, severe blood loss, food poisoning, chemotherapy, radiation therapy, severe trauma or liver diseases, immunocompromised conditions. For this, the present invention provides use of an ectophosphatase for the preparation of a medicament for the prophylaxis of a mammal at risk of inflammatory diseases. | 2011-03-03 |
| 20110052561 | OSTEOLYSIS TREATMENT - Methods and treatments for osteolysis employing interleukin-1 receptor antagonist (IL-1ra). Activating production of interleukin-1 receptor antagonist includes incubating adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells with polyacrylamide beads to produce a solution rich in interleukin-1 receptor antagonist. Activating the production of interleukin-1 receptor antagonist includes using an implantable device loaded with adipose tissue, adipocytes, whole blood, platelet rich plasma, and/or isolated white blood cells. Methods for treating osteolysis at the site of an artificial joint in a patient include administering and/or inserting the solution rich in interleukin-1 receptor antagonist and/or the implantable device, respectively. | 2011-03-03 |
| 20110052562 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS - Compounds useful as Rho kinase inhibitors according to formula IA or IB: wherein A, B, D, E, R | 2011-03-03 |
| 20110052563 | GONADAL FUNCTION IMPROVING AGENTS - Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility, hormone-sensitive cancers, endometriosis, etc. Metastin and its receptors are useful for screening for these pharmaceuticals. | 2011-03-03 |
| 20110052564 | ENHANCEMENT OF IMMUNOGENICITY OF ANTIGENS - The invention provides means and methods for producing and/or selecting immunogenic compositions, comprising providing said composition with at least one crossbeta structure and testing at least one immunogenic property. | 2011-03-03 |
| 20110052565 | NON-AGGREGATING HUMAN VH DOMAINS - The present invention relates to non-aggregating VH domains or libraries thereof. The V | 2011-03-03 |
| 20110052566 | COGNITIVE FUNCTION - Inhibition of eIF-2α phosphorylation can be used to improve cognitive function and/or to treat dementia, including Alzheimer's Disease. In particular, this can be achieved by inhibiting the kinase activity of PKR in a non-toxic manner. | 2011-03-03 |
| 20110052567 | Methods Compositions, Uses, and Kits Useful for Vitamin D Deficiency and Related Disorders - Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders; related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism-related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered. | 2011-03-03 |
| 20110052568 | TABLET COMPRISING NATURAL ALLICIN AND METHOD FOR PRODUCING THE SAME - A tablet including 1,000 weight parts of 21-90% natural allicin powder, 10-30 weight parts of 50-95% sesamin, 10-30 weight parts of 50-95% IgY or IgG, and a release agent. The allicin content of the tablet is 200-800 mg/g. The allicin tablet has high allicin content and capability of anti-bacteria and anti-inflammation, and can be administered based on the body weight of an animal in need thereof but causes no side effects. A method for producing the allicin tablet by mixing and uniformly stirring starch, garlic powder, and natural allicin powder to yield a mixture, adding the natural sesamin, Ig Y or Ig G, and magnesium stearate to the mixture, uniformly stirring, and tabletting. | 2011-03-03 |
| 20110052569 | MOLECULES AND METHODS FOR TREATMENT OF DIABETES - Described are antibodies that specifically recognize and bind the epitope of glutamate decarboxylase (GAD65) that is bound by antibody b96 11, and anti-idiotypic antibodies that are capable of competing with GAD65 for binding with b96.11 and competitively inhibit such binding. These antibodies can be provided in the form of a pharmaceutical composition and can be used in methods for delaying the onset of Type 1 diabetes and for inhibiting insulitis and other diabetic symptoms. Also provided are methods for detecting a susceptibility to Type 1 diabetes in a subject and for detecting the presence of anti-idiotypic antibodies to GAD65. The method comprises contacting a specimen with an antibody of the invention. The method further comprises detecting binding of the molecule of the specimen. The absence (or relative absence) of binding is indicative of susceptibility to Type 1 diabetes and of the absence of anti-idiotypic antibodies. | 2011-03-03 |
| 20110052570 | METHOD TO PROGNOSE RESPONSE TO ANTI-EGFR THERAPEUTICS - The present invention provides methods to determine the likelihood of effectiveness of an EGFR targeting treatment in a subject affected with a tumor based on the expression of EGFR of endothelial cells associated with the tumor. The present invention also provides methods of treating a subject affected with, or at risk for developing cancer with an EGFR targeting treatment and methods to screen for an EGFR targeting treatment. | 2011-03-03 |
| 20110052571 | METHOD FOR TREATING IDIOPATHIC THROMBOCYTOPENIC PURPURA USING MONOCLONAL ANTIBODIES - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcγ receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby or for uses such as idiopathic thrombocytopenic purpura (ITP). | 2011-03-03 |
